Valeo Financial Advisors’s Emergent Biosolutions EBS Stock Holding History

Valeo Financial Advisors’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-50	Closed	-$4K	–	2067
2020 Q4	$4K	Sell	50 -250	-83%	-$22.9K	﹤0.01%	1402
2020 Q3	$31K	Buy	300 +95	+46%	+$10.2K	﹤0.01%	802
2020 Q2	$16K	Buy	205 +8	+4%	+$596	﹤0.01%	1133
2020 Q1	$12K	Hold	197	–	–	﹤0.01%	1023
2019 Q4	$11K	Sell	197 -6	-3%	-$325	﹤0.01%	1079
2019 Q3	$11K	Buy	203 +4	+2%	+$186	﹤0.01%	999
2019 Q2	$10K	Buy	199 +158	+385%	+$7.57K	﹤0.01%	1019
2019 Q1	$2K	Hold	41	–	–	﹤0.01%	1342
2018 Q4	$2K	Hold	41	–	–	﹤0.01%	1269
2018 Q3	$3K	Buy	+41	New	+$2.39K	﹤0.01%	1338

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Valeo Financial Advisors's EBS Position: Q1 2021 in Review

Valeo Financial Advisors sold out of Emergent Biosolutions (EBS) in Q1 2021, closing a stake of 50 shares — an estimated $4K sold.

Valeo Financial Advisors first reported a position in EBS in Q3 2018 and held it in 10 quarters. The position peaked at $31K in Q3 2020. 340 funds tracked by Wall St. Rank hold EBS as of Q1 2021.

Valeo Financial Advisors reported no remaining Emergent Biosolutions position as of Q1 2021 after selling out during the quarter.
Valeo Financial Advisors sold 50 Emergent Biosolutions shares in Q1 2021, an estimated $4K.
Valeo Financial Advisors first reported a position in Emergent Biosolutions in Q3 2018 and held it in 10 quarters.
Valeo Financial Advisors's Emergent Biosolutions position peaked at $31K in Q3 2020.
340 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2021.

Based on Valeo Financial Advisors's 13F filing for Q1 2021, filed 12 Apr 2021.